Long-term engraftment, graft-vs.-host disease, and immunologic reconstitution after experimental transplantation of allogeneic peripheral blood cells from G-CSF-treated donors.
Peripheral blood cells (PBPC) are an alternative source of bone marrow for allogeneic transplantation. Reports from recent clinical trials granulocyte colony-stimulating factor (G-CSF)-mobilized PBPC for allogeneic transplantation show incidence and severity of graft-vs.-host disease (GVHD) similar to those observed in conventional bone marrow transplantation (BMT), despite the presence of 10- to 20-fold more T cell in the PBPC inoculum. In the present study, we examined the effects of pretreatment of donors with G-CSF on GVHD, long-term engraftment, and lymphocyte reconstitution in a murine parent-->F1 model (B6.Ly-5a-->B6d2F1) using splenocytes as a source of peripheral progenitor cells. Recipients of splenocytes from G-CSF-treated donors experienced less mortality from acute GVHD and showed sustained weight gain by day 100 after transplantation. At that time, there was no histological evidence od GVHD in either liver or gut. Recipients of splenocytes from G-CSF-treated donors showed complete donor engraftment within 1 month, which was sustained until the end of the observation period. In contrast, recipients of T cell-depleted splenocytes showed slower donor engraftment and persistent donor/host chimerism. In addition, lymphocyte phenotype and function in mice receiving splenocytes from G-CSF-treated donors was significantly restored by day 100 after transplantation. Thus, the use of G-CSF-mobilized PBPC may provide significant advantages to conventional BMT by reducing GVHD without impairing long-term engraftment and immunologic reconstruction.
Pan
L
L
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Bressler
S
S
Cooke
K R
KR
Krenger
W
W
Karandikar
M
M
Ferrara
J L
JL
D000818:Animals; D016207:Cytokines / Q000096:biosynthesis / Q000187:drug effects; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology* / Q000628:therapy; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D007109:Immunity; D051379:Mice; D013154:Spleen / Q000166:cytology / Q000187:drug effects; D015996:Survival Rate; D013601:T-Lymphocytes / Q000187:drug effects / Q000502:physiology; D013997:Time Factors; D016378:Tissue Transplantation; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000276:immunology* / Q000401:mortality
D016207:Cytokines; D016179:Granulocyte Colony-Stimulating Factor